Innovative immunotherapies against cancer
Transgene
Euronext-listed biotechnology company that is 69% owned by Institut Mérieux.
Strasbourg (France)
Areas of activity
Viral-based immunotherapies, with therapeutic vaccines and oncolytic virus, against cancer and infectious diseases.
GMP-compliant pilot production unit.
close to
160
employees
IMMUNOTHERAPY FOR CANCER
AND INFECTIOUS DISEASES
Transgene is a biotechnology company that develops therapeutic vaccines and oncolytic viruses to treat cancer and infectious diseases.
Transgene’s immunotherapy products are designed to induce or enhance an immune response to specific tumors or infected cells. Their goal is to give the patient’s immune system the ability to fight off the disease itself. Transgene’s products use viral vector technology to directly or indirectly kill infected cells.
These innovative approaches are appropriate candidates for combinations with existing and future therapeutic solutions (chemotherapy, surgery, radiotherapy, antiviral therapy, immune checkpoint inhibitors), and should meet a number of unmet medical needs. Immuno-oncology is evolving fast and is progressively becoming a pillar of future cancer treatments.
APPLIED RESEARCH
& VIRUS ENGINEERING
With proven expertise in applied research, virus engineering, and pre-clinical and clinical developments, Transgene targets important public health needs.
With its two innovative platforms, myvac® and Invir.IO®, Transgene is positioned as an immuno-oncology player at the cutting edge of precision medicine.
- The myvac® platform is based on an MVA (Modified Ankara Virus) vector with established and recognized safety, biological activity and ability to induce an immune response against tumor antigens. With this platform, Transgene is developing individualized immunotherapies incorporating tumor mutations identified and selected thanks to an artificial intelligence provided by its partner NEC.
- Invir.IO® is a platform based on Transgene’s expertise in viral vector engineering, enabling the design of a new generation of multifunctional oncolytic viruses that modulate the tumoral microenvironment and enhance anti-tumor activity.
Transgene’s work includes a strategy for identifying “biomarkers” that are prognostic and predictive of response to treatment, making it possible to improve product efficacy with a view to personalized medicine.
In collaboration with academic and hospital research, its teams are working on the design of innovative immunotherapies, preclinical development and clinical trials of products. To date, four Transgene products are in clinical trials. The company’s strategy is to generate favorable initial clinical results, in order to secure co-development or partnership agreements with industry.
